CJC-1295 Without DAC 5mg + Ipamorelin – 5mg Dosage Protocol

What is this Blend?

This formulation combines two distinct growth hormone secretagogues (GHS) that act synergistically to maximize the pulsatile release of endogenous growth hormone (GH) from the anterior pituitary gland:

CJC-1295 Without DAC (Modified GRF 1-29): A synthetic 29-amino-acid peptide analogue of Growth Hormone-Releasing Hormone (GHRH). It features four amino acid substitutions ( $D\text{-Ala}^2, \text{Gln}^8, \text{Ala}^{15}, \text{Leu}^{27}$ ) that significantly enhance its structural stability against enzymatic degradation compared to native GHRH. It mimics endogenous GHRH to trigger the production and release phase of GH pulses.
Ipamorelin: A highly selective synthetic pentapeptide that functions as a ghrelin receptor mimetic. It binds to the growth hormone secretagogue receptor (GHS-R1a) to induce acute GH release while concurrently dampening somatostatin—the body’s inhibitory “brake” on growth hormone. Crucially, Ipamorelin stimulates GH without causing significant increases in cortisol, prolactin, or adrenocorticotropic hormone (ACTH).

By combining a GHRH analogue and a ghrelin mimetic, this blend exploits dual-receptor activation pathway synergy, yielding a highly magnified GH pulse that preserves physiological negative feedback loops. This blend remains an experimental material supplied strictly for in-vitro laboratory testing and metabolic evaluation models.

Potential Areas of Research

Synergistic GH Pulsatility: Studied for its ability to produce a significantly greater GH surge than either peptide administered in isolation.

Metabolic & Composition Optimization: Evaluated in metabolic models for its downstream impacts on elevating circulating Insulin-like Growth Factor 1 (IGF-1), reducing adipose tissue, and supporting lean protein synthesis.

Recovery & Cellular Repair: Profiled in tissue models for accelerated cellular regeneration, injury recovery timelines, and slow-wave sleep architecture enhancement.

Preserved Homeostasis: Investigated because it stimulates physiological GH rhythms without suppressing natural glandular feedback mechanisms or elevating stress hormones.

CJC-1295 No DAC + Ipamorelin (5 mg + 5 mg) Dosage Protocol

Total Blend Mass: 10 mg per vial (5 mg CJC-1295 No DAC + 5 mg Ipamorelin in a 1:1 ratio)

Reconstitution: 3.0 mL Bacteriostatic Water

Total Concentration: ~3.33 mg/mL total peptide (~1.67 mg/mL of CJC-1295 No DAC + ~1.67 mg/mL of Ipamorelin)

Administration: Subcutaneous Injection

Frequency: Once daily (typically at bedtime to synchronize with natural nocturnal GH pulsatility)

Dosage Chart

Phase

Target Dose (Per Peptide)

Total Blend Mass

Weeks 1–2 (Titration)

100 mcg each

200 mcg total

Weeks 3–4 (Intermediate)

150 mcg each

300 mcg total

Weeks 5–6 (Advanced)

200 mcg each

400 mcg total

Weeks 7–12+ (Target)

250–300 mcg each

500–600 mcg total

Protocol Note: To prevent nutrient-induced suppression of the GH pulse, injections must be administered on an empty stomach. The research subject model should be fasted for at least 2 hours prior to injection, and remain fasted for at least 30 minutes afterward.

Reconstitution

Allow the lyophilized 10 mg blend vial to transition to room temperature before mixing to prevent condensation accumulation.
Slowly introduce 3.0 mL of sterile bacteriostatic water into the vial using a sterile syringe.
Direct the liquid stream down the inner glass wall of the vial, letting the diluent trickle down slowly to avoid foaming or structural agitation.
Gently swirl or roll the vial between your palms until the crystalline cake completely dissolves. Do not shake.
Confirm visually that the solution is transparent and colorless. Discard immediately if cloudiness, precipitation, or floaters form.

Storage

Before reconstitution: Store refrigerated at 2–8°C (35.6–46.4°F) for routine lab use, or frozen at −20°C (−4°F) or below for extended long-term molecular preservation. Keep in a dark space protected from UV light.
After reconstitution: Store refrigerated at 2–8°C (35.6–46.4°F) and use within 14 days.
Important: Do not freeze the peptide blend once it has been mixed into a liquid solution. Avoid all repeated freeze-thaw cycles and rough physical handling to prevent structural degradation of the amino acid chains.

Injection & Handling Technique

To maintain strict experimental control and reduce local tissue irritation, execute standard subcutaneous handling:

Site Selection: Inject subcutaneously into the fatty layer of the abdomen (at least 2 inches outside the navel radius), the outer thighs, or the back of the upper arms.
Systematic Site Rotation: Systematically shift the injection coordinates daily across different quadrants to mitigate local skin irritation, swelling, or the development of lipohypertrophy (fibrotic fat deposits).
Administration Speed: Depress the syringe plunger slowly and steadily over 5 seconds. Hold the needle in place for an additional 2 to 3 seconds before withdrawing to prevent solution backflow or tracking.

Technical Research Note

Because this blend combines a GHRH analogue and a ghrelin receptor agonist, it produces a distinct, high-amplitude peak in plasma growth hormone levels. Researchers should expect potential dose-dependent side effects in test models, including transient facial flushing, a mild sensation of warmth, or a temporary headache immediately following injection due to rapid vasodilation. Prolonged application may cause mild water retention or joint sensitivity (arthralgia) as downstream IGF-1 levels climb. This blend is contraindicated in research models with active malignant neoplasms due to the theoretical risks associated with elevating systemic growth factors.

Regulatory Compliance Disclaimer

IMPORTANT NOTICE: This product is engineered and distributed exclusively for in-vitro laboratory testing and scientific research applications. It is strictly NOT a medicine, drug, or dietary supplement and is not intended for human consumption or veterinary use. This compound has not been evaluated or approved by the MHRA, FDA, or EMA. Any use outside of legitimate, controlled laboratory environments is strictly prohibited. The purchaser assumes all liability for the safe handling and legal compliance of this material.

View Supplier

References

— Alba et al.: Long-acting CJC-1295 restores normal growth in growth hormone-releasing hormone (GHRH) knockout mice

— Veldhuis et al.: Continuous CJC-1295 administration preserves physiological pulsatile growth hormone (GH) secretion

— Sermorelin: Clinical review of its diagnostic and therapeutic applications in growth hormone (GH) deficiency

— Subcutaneous injection technique: recommended anatomical sites and administration guidance

— Injection best practices: aseptic technique, preparation, and safe administration procedures